TX-001HR, a combination of 17β-estradiol and progesterone, was evaluated in a randomized controlled trial for its effects on sleep quality in postmenopausal women experiencing vasomotor symptoms (VMS). The study included 1,835 participants (mean age 55) and tested four different dosages over 12 months. Results showed significant improvements in sleep quality,
